[ad_1]
Illustration The samples of the Corona virus were shown by one of the doctors. Photo: BETWEEN
jpnn.com – The Food and Drug Administration (FDA) has authorized the use of Remdesivir to treat patients with COVID-19. The FDA authorized Gilead Sciences Inc. as the manufacturer of Remdesivir to use the antiviral medication in patients infected with the novel coronavirus.
The FDA’s decision was not surprising. In fact, new research has revealed the possibility that Remdesivir is the most effective drug in the fight against COVID-19.
Remdesivir is one of several medications that are tested on COVID-19 patients worldwide. Therefore, the drug is very effective against enzymes that play an important role in the spread of the new type of coronavirus.
The Journal of Biological Chemistry in mid-April reported the results of the latest research on Remdesivir. The drug, which was developed in 2014 to fight the Ebola epidemic, was found to be helpful in fighting the new coronavirus.
“Remdesivir is a very strong inhibitor for coronavirus polymerase, and if it targets polymerase, the virus cannot spread. Therefore, it is a very logical target for treatment,” said Matthias Gotte as the study’s author.
The head of the department of medical and immunological microbiology at the University of Alberta, Canada, explained that evidence from recent and previous studies in animal and cell cultures showed that Remdesivir could be classified as an antiviral that reacts directly to new coronaviruses. In February, the Gotte lab released a study showing how Remdesivir fights the Middle East respiratory syndrome virus (MERS).
The MERS virus is still associated with SARS-CoV-2, which is none other than the virus that causes COVID-19. “We got almost the same results as we previously reported with MERS, so we see that Remdesivir is a very strong inhibitor for coronavirus polymerase,” Gotte concluded.(fny / jpnn)
[ad_2]
